Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
This study investigates miRNA-mediated regulation of PD-L1, focusing on miRp and miRp as novel therapeutic targets and predictive biomarkers for pembrolizumab response. Through miRNA sequencing and functional assays, miRp and miRp were identified as key modulators of PD-L1 in drug-resistant ENKTL cells, with their roles validated via ribonucleoprotein immunoprecipitation and luciferase reporter assays.
Additionally, low serum levels of miRp were associated with reduced pembrolizumab efficacy, positioning miRp as a promising predictive biomarker for immune checkpoint blockade.
These findings suggest that pre-treatment assessment of serum miRp could guide pembrolizumab therapy in ENKTL, optimizing treatment outcomes. Validation in larger cohorts is necessary to confirm the utility of miRp as a predictive biomarker for ENKTL immunotherapy. The presence of EBV in lymphoma cells is associated with the upregulation of programmed death ligand 1 PD-L1 , which binds to programmed cell eath protein 1 PD-1 on effector T cells 2.
Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, which target PD-1, have demonstrated potential in interrupting this interaction and offer therapeutic advantages in various cancers, including hematologic malignancies 3. Specifically, pembrolizumab is considered an effective treatment option for patients with relapsed or refractory ENKTL 4 , 5.
